0RC7 Stock Overview
A biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Hansa Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 30.81 |
| 52 Week High | SEK 57.30 |
| 52 Week Low | SEK 22.08 |
| Beta | 1.46 |
| 11 Month Change | -22.86% |
| 3 Month Change | -42.22% |
| 1 Year Change | 18.23% |
| 33 Year Change | -65.92% |
| 5 Year Change | -75.59% |
| Change since IPO | -25.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RC7 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -3.4% | -5.2% | 0.8% |
| 1Y | 18.2% | -20.1% | 6.6% |
Return vs Industry: 0RC7 exceeded the UK Biotechs industry which returned -20.1% over the past year.
Return vs Market: 0RC7 exceeded the UK Market which returned 6.6% over the past year.
Price Volatility
| 0RC7 volatility | |
|---|---|
| 0RC7 Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RC7's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RC7's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 135 | Søren Tulstrup | www.hansabiopharma.com |
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.
Hansa Biopharma AB (publ) Fundamentals Summary
| 0RC7 fundamental statistics | |
|---|---|
| Market cap | SEK 2.08b |
| Earnings (TTM) | -SEK 654.78m |
| Revenue (TTM) | SEK 189.39m |
11.0x
P/S Ratio-3.2x
P/E RatioIs 0RC7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RC7 income statement (TTM) | |
|---|---|
| Revenue | SEK 189.39m |
| Cost of Revenue | SEK 88.19m |
| Gross Profit | SEK 101.20m |
| Other Expenses | SEK 755.98m |
| Earnings | -SEK 654.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | -9.66 |
| Gross Margin | 53.43% |
| Net Profit Margin | -345.73% |
| Debt/Equity Ratio | -294.7% |
How did 0RC7 perform over the long term?
See historical performance and comparison